Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 4/20 | 0.46 |
| ▸ | PARP15 | Q460N3 | 3/20 | 0.46 |
| ▸ | ELANE | P08246 | 1/20 | 0.46 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 8/20 | 0.37 |
| ▸ | ACACB | O00763 | 1/20 | 0.37 |
| ▸ | ACACA | Q13085 | 1/20 | 0.37 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.36 |
| ▸ | KIT | P10721 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5215684 | 0.88 | PIK3CD (0.40) | ELANEDYRK1APIK3CDESR1 | |
| SCHEMBL5216211 | 0.85 | SMN1; SMN2 (0.39) | ELANEDYRK1APIK3CDESR1 | |
| SCHEMBL6843911 | 0.85 | ESR1 (0.42) | DYRK1AFFAR1ESR1 | |
| SCHEMBL5215855 | 0.85 | ESR1 (0.42) | DYRK1AFFAR1ESR1 | |
| SCHEMBL5214032 | 0.85 | SMN1; SMN2 (0.39) | ELANEDYRK1APIK3CDESR1 | |
| SCHEMBL5210876 | 0.84 | DYRK1A (0.38) | DYRK1APIK3CDESR1 | |
| SCHEMBL4771835 | 0.84 | ESR1 (0.42) | DYRK1AFFAR1ESR1 | |
| SCHEMBL5212869 | 0.82 | ESR1 (0.42) | PARP10DYRK1APIK3CDESR1ACACB | |
| SCHEMBL5217164 | 0.82 | PTGDR2 (0.41) | ELANEDYRK1APIK3CDESR1 | |
| SCHEMBL6021255 | 0.82 | STING1 (0.46) | PARP10PARP15ELANEDYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1636213-B1 | 3-ARYLOXY AND 3-HETEROARYLOXY SUBSTITUTED BENZO(B) THIOPHENES AS THERAPEUTIC AGENTS WITH PI3K ACTIVITY | WARNER LAMBERT CO (US) | 2007-06-13 | — | — | EP | disclosed |
| US-20040259926-A1 | 3-Aryloxy and 3-heteroaryloxy substituted benzo[b]thiophenes as therapeutic agents | BRUENDL MICHELLE M (US) | 2004-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259926-A1 | 3-Aryloxy and 3-heteroaryloxy substituted benzo[b]thiophenes as therapeutic agents | MALT1, CYP1B1, CYP4B1 | PARP10 3074/4885PARP15 2170/4885ELANE 4253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.